Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280565 · ClinicalTrials.gov registry record · Phase 3
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
A Phase 3 study, sponsored by AB Science.
- Terminated
- Registry status
- Phase 3
- Development phase
- 134
- Enrollment target
NCT01280565 is a Phase 3 study that was terminated before completion, run by AB Science. The registered enrollment target is 134 participants.
The verdict
NCT01280565, a Phase 3 study, was terminated before completion, sponsored by AB Science.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 134 participants
- Enrollment target
Study Summary
The objective is to assess the efficacy and safety of masitinib at 7.5 mg/kg/day in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-Kit and who have not previously been treated for melanoma.
Interventions
- DRUG Dacarbazine
- DRUG Masitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2011-01 |
| Est. Completion | 2019-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01280565
The ClinicalTrials.gov registry entry for NCT01280565 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AB Science, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dacarbazine is the first listed.
NCT01280565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01280565 about?
NCT01280565 is a clinical study titled "Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit". The objective is to assess the efficacy and safety of masitinib at 7.5 mg/kg/day in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-Kit and who have not previously been treated for melanoma.
What is the current status of trial NCT01280565?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 134 participants. The study started on 2011-01. Estimated completion is 2019-08.
What interventions are being tested in trial NCT01280565?
The interventions under investigation include: Dacarbazine (DRUG), Masitinib (DRUG).
Who is sponsoring clinical trial NCT01280565?
This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.